Piedmont Eye Center Inc | Lynchburg, VA
Status and phase
Conditions
Treatments
About
In this prospective, phase 2b, multicenter, randomized, double-masked, vehicle-controlled, parallel-arm study, approximately 880 subjects with moderate to severe dry eye disease (DED) will be randomly assigned (1:1) to receive either TL-925 or vehicle as topical ophthalmic eye drops administered bilaterally BID.
The study will comprise two phases: a two-week screening phase/run-in and a six-week double-masked treatment phase.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
880 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
Yulia Khalina; John Mei
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal